| Date | Form | Description | Docs | XBRL | Pages |
| 08/17/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 08/17/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 08/17/20 | 8-K | Current report filing |
|
25 | |
| 07/20/20 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 07/02/20 | DEF 14A | Definitive proxy statements |
|
46 | |
| 07/02/20 | 8-K | Current report filing |
|
6 | |
| 06/22/20 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
46 | |
| 06/17/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 06/16/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 06/12/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...